Abstracts tagged "Lupus nephritis"

Abstract Number: 1666 • 2014 ACR/ARHP Annual Meeting
The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus
Hiroshi Kajiyama¹, Keiju Hiromura², Daisuke Ikuma¹, Hidekazu Ikeuchi², Hiroyuki Kurosawa³, Yoshiaki Hirayama³, Fumio Gondaira³, Masanori Hara⁴, Yoshihisa Nojima² and Toshihide Mimura⁵, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ³Department of reagent research and development, Denka Seiken Co. Ltd., Niigata, Japan, ⁴Department of Pediatrics, Yoshida Hospital, Niigata, Japan, ⁵Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose Podocytes are glomerular visceral epithelial cells, whose number decrease due to death and/or detachment from capillary wall leads to severe proteinuria and end stage…
Abstract Number: 1663 • 2014 ACR/ARHP Annual Meeting
Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and prevalence is estimated to be 50-60%. Recently, variable responses to induction…
Abstract Number: 1262 • 2013 ACR/ARHP Annual Meeting
Comparison Of Remission Rates For Pediatric Membranous Plus Proliferative Lupus Nephritis Versus Isolated Proliferative Lupus Nephritis: An Analysis Of The Childhood Arthritis and Rheumatism Research Alliance Registry
Alexis Boneparth¹, Norman T. Ilowite¹ and The CARRA Registry Investigators², ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Duke Clinical Research Institute, Durham, NC
Background/Purpose: Lupus nephritis (LN) affects many patients with pediatric systemic lupus erythematosus (pSLE) and is a significant cause of disease morbidity. Inability to achieve remission…
Abstract Number: 1263 • 2013 ACR/ARHP Annual Meeting
Childhood-Onset Systemic Lupus Erythematosus In Ontario: Long Term Outcomes In a Population-Based Cohort With Universal Health Care Coverage
Deborah M. Levy¹, Nadia Gunraj², Janet E. Pope³, J. Carter Thorne⁴, Wesley Fidler⁵, Peter B. Dent⁶, Johannes Roth⁷, Roberta A. Berard⁸, Murray Berall⁹, Astrid Guttmann¹⁰ and Earl D. Silverman¹¹, ¹Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Medicine/Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, ON, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Rheumatology, St. Joseph's Hospital, Thunder Bay, ON, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸Children's Hospital of Western Ontario, London, ON, Canada, ⁹Nephrology, Humber River Regional Hospital, Toronto, ON, Canada, ¹⁰Pediatrics, Institute for Clinical Evaluative Sciences, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Little is known about the long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care; however, linking clinical data to administrative…
Abstract Number: 645 • 2013 ACR/ARHP Annual Meeting
Transcript Profiling Of Blood and Kidney Biopsies From Chinese Patients With Lupus Nephritis Reveals Concordant Activation Of Type I IFN Signaling In The Blood and Kidney, Reduced B Cell Presence In The Blood, and Increased Macrophages In The Kidney
Zheng Liu¹, Chris, A. Morehouse¹, Xinfang Huang², Philip Brohawn¹, Nan Shen², Yihong Yao¹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Dept of Rheumatology, Shanghai Ren Ji Hospital, Shanghai, China
Background/Purpose: Up-regulated expression of type I interferon-regulated genes has consistently been observed within the peripheral blood in a large proportion of patients with active systemic…
Abstract Number: 582 • 2013 ACR/ARHP Annual Meeting
A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Current pharmacotherapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN) includes combinations of nonsteroidal anti–inflammatory drugs (NSAIDs), antimalarials (AMs), glucocorticoids (GCs), and cytotoxic…
Abstract Number: 589 • 2013 ACR/ARHP Annual Meeting
A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Patient satisfaction with disease control is an important component of overall health and well-being. Current treatment options for systemic lupus erythematosus (SLE) ±lupus nephritis…
Abstract Number: 594 • 2013 ACR/ARHP Annual Meeting
Renal Biopsy Findings In Lupus Patient With Insignificant Proteinuria : Relation To Disease Activity and Clinical Manifestations
Abdel Azeim M. Al-Hefny¹, Samah El-bakry², Sameh A. Mobasher³, Ola H. Nada⁴ and Nouran Abaza⁵, ¹Department of Internal Medicine and Rheumatology, Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Cairo, Egypt, ²Department of Internal Medicine and Rheumatology, Assistant professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ³Department of Internal Medicine and Rheumatology, Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ⁴Department of Pathology, Faculty of Medicine, Ain Shams University, Lecturer of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ⁵Physical medicine, Rheumatology and Rehabilitation, Lecturer of Physical medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Background/Purpose: Lupus nephritis (LN) remains one of the most serious manifestations of systemic lupus erythematosus (SLE) and is associated with significant morbidity and mortality. Early…
Abstract Number: 600 • 2013 ACR/ARHP Annual Meeting
Factors Associated With Long-Term Renal Function Deterioration In Lupus Nephritis Treated Initially With Combined Prednisolone and Mycophenolate Mofetil (MMF) Or Tacrolimus (Tac)
Chi Chiu Mok¹, Chi Hung To¹, King Yee Ying², Cheuk-Wan Yim³ and Woon Leung Ng⁴, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Department of Medicine, Princess Margaret Hospital, Hong Kong, Hong Kong, ³Dept of Medicine, United Christian Hospital, Hong Kong, Hong Kong, ⁴Medicine, United Christian Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the risk factors for renal function decline in patients with lupus nephritis treated initially with combined steroid and MMF or Tac.Methods: Data…
Abstract Number: 580 • 2013 ACR/ARHP Annual Meeting
Lupus Nephritis Flares Precipitated By Switching From Mycophenolate Mofetil to Azathioprine in Pre-Pregnancy Planning
Natasha Jordan and David D'Cruz, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that affects women of childbearing age. Lupus nephritis is a major cause of morbidity and…
Abstract Number: L18 • 2013 ACR/ARHP Annual Meeting
Long-Term Evaluation of Bone Mineral Density Change in Women Receiving Depot Leuprolide Acetate during Cyclophosphamide Therapy for Severe Lupus Nephritis
Nathan Meier¹ and Mary Anne Dooley², ¹Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Cohort studies demonstrate that 11-83% of female patients receiving cyclophosphamide (CYC) for treatment of severe manifestations of SLE develop premature ovarian failure (POF), dependent…
Abstract Number: 2719 • 2013 ACR/ARHP Annual Meeting
Urinary Angiostatin As Alternative To Biopsy In lupus Nephritis Patients Among Egyptian
Shereen Algergawy¹, Osama Alshaar² and Rania Zakaria³, ¹rheumatology and rehabilitation, associate prof at benha university faculty of medicine rheumatology and rehabilitation department Egypt, cairo, Egypt, ²clinical pathology, benha university faculty of medicine, benha, Egypt, ³pathology, benha university faculty of medicine, benha, Egypt
Background/Purpose: Lupus nephritis (LN) is one of the most frequent manifestations of SLE and can be present in 60% of SLE patients. Kidney biopsy remains…
Abstract Number: 2547 • 2013 ACR/ARHP Annual Meeting
Anti-Ribosomal P Antibody Has a Protective Role In The Development Of Chronic Kidney Disease In Patients With Lupus Nephritis
Kyung-Eun Lee¹, Dong-Jin Park¹, Tae-Jong Kim², Yong-Wook Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: Anti-ribosomal P antibody (anti-P) in patients with systemic lupus erythematosus (SLE) is associated with neuropsychiatric manifestation. Of interest, recent studies have suggested that anti-P…
Abstract Number: 1444 • 2012 ACR/ARHP Annual Meeting
HLA-DR3 Controls Autoantibody Response to Sm in NZM2328.DR3+.AE0 Transgenic Mice
Vaidehi R. Chowdhary¹, Chao Dai², Shu Man Fu² and Chella S. David³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Medicine/CIIR/Rheumatology, University of Virginia Health System, Charlottesville, VA, ³Departement of Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Large genome wide scans have confirmed the strong association of HLA -DR3 with risk of developing SLE and antibody response to Sm which is specific…
Abstract Number: 1433 • 2012 ACR/ARHP Annual Meeting
Persistent Dyslipidemia Is a Risk Factor of Progression to Chronic Kidney Disease in Patients with Lupus Nephritis
Dong-Jin Park¹, Kyung-Eun Lee¹, Tae-Jong Kim¹, Yong-Wook Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: To investigate the effect of dyslipidemia at baseline and during follow-up period on the progression to chronic kidney disease (CKD) in patients with biopsy-proven…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].